The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

Boston Scientific (NYSE:BSX) shares were down 5% in morning trading Wednesday following news that the company has paused a study for its new FARAPULSE Pulse Field Ablation system due to unforeseen ...

In this article, we are going to take a look at where Boston Scientific Corporation (NYSE:BSX ... medical devices work ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Boston Scientific Corp. signed a definitive agreement to acquire Cortex Inc., from Ajax Health Inc. to develop an integrated mapping and ablation solution for cardiac arrhythmias. Cortex’s Optimap ...

Massachusetts-based Boston Scientific generates most of its revenue from sales of its heart devices, such as pacemakers and stents. It also makes equipment to diagnose and treat a range of ...

Boston Scientific stock toppled Wednesday after the medtech announced it had paused enrollment in a study of its pulsed field ablation technology. Please watch the video at Investors.com - How To ...

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.

Boston Scientific is keeping the ball rolling in pulsed field ablation, posting 177% electrophysiology growth in the third quarter powered by the launch of its Farapulse system for atrial ...

Investors with a lot of money to spend have taken a bearish stance on Boston Scientific (NYSE:BSX). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Boston Scientific has launched a docuseries campaign to remove the stigma of male incontinence. Across the videos, the campaign tells the stories of how incontinence upended the lives of three men ...

Outlook: Boston Scientific forecasts net sales growth for 2024 of approximately 16.5% on a reported basis and 15% on an organic basis, compared to prior guidance of 13.5%-14.5% and 13%-14% ...